Cardiovascular Health

Aspirin may reduce the risk of blood clots in patients who cannot use traditional anticoagulants, new research suggests.

Several new anticoagulants have entered the US market in recent years, but research to find reversal agents for these drugs is ongoing.

Digoxin increases risk of death in patients with newly diagnosed atrial fibrillation.

Researchers evaluated more than 2 decades of evidence on atrial fibrillation patients taking vitamin K antagonists.

Researchers evaluated the risk of cardiovascular outcomes in atrial fibrillation patients with a history of falls.

A recent investigation found a significant increase in hospitalization rates for patients with atrial fibrillation in the United States.

When nonwhite heart attack patients were able to obtain cardiovascular medications without a copayment, their readmission rates for a major vascular event or coronary revascularization dropped significantly.

Current and recent users of nonsteroidal anti-inflammatory drugs were significantly more likely to develop atrial fibrillation, according to the results of a new study.

Trial finds that spironolactone significantly reduced hospitalization for heart failure in heart failure patients with a preserved ejection fraction but failed to decrease the incidence of the trial's primary composite outcome.

The results of a new study suggest that statin patients may have a false sense of security, leading them to believe the medication can offset the effects of a poor diet and lack of exercise.

According to a recent study, one-fifth of those aged 60 or older who were candidates for pharmacologic therapy under JNC 7 would rely on lifestyle blood pressure control under JNC 8.

The Target: Stroke initiative reduced the time before acute ischemic stroke patients were treated with intravenous tissue plasminogen activator, leading to reduced rates of in-hospital mortality and intracranial hemorrhage.

New atrial fibrillation treatment guidelines from the American Heart Association and American College of Cardiology clarify the role of novel oral anticoagulants and rate/rhythm control medications.

New guidelines from the American Heart Association, American College of Cardiology, and Heart Rhythm Society address use of new oral anticoagulants as well as warfarin to treat atrial fibrillation.

Patients who self-monitored their international normalized ratio weekly achieved significantly better control than those who did so less frequently, but all home monitoring patients performed well, according to a new study.

New study finds that use of azithromycin and levofloxacin are associated with significantly increased risk of death and serious arrhythmia, backing up a safety warning issued by the FDA in March 2013.

Researchers find that full implementation of recently released dyslipidemia management guidelines would help prevent 475,000 additional cardiovascular events.

A new review summarizes the natural history of cardiomyopathies presenting with atrial fibrillation and the importance of managing underlying pathologies.

Research from the United Kingdom suggests that getting the influenza vaccine, especially early in the flu season, significantly reduces one's risk of stroke.

Pharmacists can learn about educating patients on the risk of stroke in atrial fibrillation, monitoring anticoagulation therapy, and participating in disease management opportunities.

The influence of mental illness on adherence among patients who should be taking warfarin is not well understood.

A recent article summarizes current knowledge and discusses challenges related to atrial fibrillation and heart failure.

A new analysis explores the characteristics of patients with permanent versus non-permanent atrial fibrillation, as well as those whose condition is controlled versus uncontrolled.

Post-myocardial infarction patients who had each of their preventive medications on hand at least 80% of the time had significantly lower rates of major vascular events or revascularization than controls.

A new study estimates the costs of treating atrial fibrillation as well as the comparative costs of treating it with warfarin and newer oral anticoagulants.

The results of a recent study identified a relationship between cardiovascular disease and cognitive decline in postmenopausal women.

Atrial fibrillation patients were more likely to suffer a stroke within the first month of initiating treatment with warfarin when compared with those not using any antithrombotic therapy, according to the results of a recent study.

According to the results of a German study published in PLOS ONE, atrial fibrillation may increase the risk for depression.

A recent study published in the Annals of Internal Medicine finds that premature atrial contraction count may improve atrial fibrillation risk model performance.